Antinuclear Antibody Test Market Size Worth USD 5.0 billion by 2031 at a CAGR of 15.0%

Increasing prevalence of autoimmune diseases among people drives the growth of the global antinuclear antibody test market. Moreover, the fact that antinuclear antibody tests are becoming more and more popular as a way to diagnose autoimmune diseases such as rheumatoid arthritis, Systemic Lupus Erythematosus, Sjogren's Syndrome, and others has supplemented the growth even more. Moreover, growing government healthcare insurance and rising awareness about autoimmune disorders are expected to create lucrative opportunities in the industry.

Allied Market Research published a report, titled, "Antinuclear Antibody Test Market by Product (Reagents & Assay Kits, Systems, Software & Services), by Technique (ELISA, Immunofluorescence Assay, Multiplex Assay), by Application (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjogren's Syndrome, Scleroderma, Others), by End-use (Hospitals, Clinical Laboratories, Physician Office Laboratories, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the global antibody test industry was estimated at $1.3 billion in 2021, and is anticipated to hit $5.0 billion by 2031, registering a CAGR of 15.0% from 2022 to 2031.

The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends. The market study is a helpful source of information for the frontrunners, new entrants, investors, and shareholders in crafting strategies for the future and heightening their position in the market.

Get Sample PDF Report with Graphs and Figures Here: https://www.alliedmarketresearch.com/request-sample/4259

Top Antinuclear Antibody Test Companies

• Bio-Rad Laboratories, Inc.
• Erba Diagnostics
• Thermo Fisher Scientific
• Antibodies Incorporated
• Trinity Biotech Plc.
• Immuno Concepts NA Ltd.
• ZEUS Scientific, Inc.
• Inova Diagnostics, Inc.
• EUROIMMUN Medizinische Labordiagnostika AG.

Antinuclear Antibody Test Market segmentation can be done based on several factors, including:

By product, the reagents & assay kits segment contributed to around three-fifths of the global antinuclear antibody test market share in 2021, and is expected to lead the trail by 2031. The same segment would also garner the fastest CAGR of 15.53% during the forecast period. Rise in the use of these kits for various research and development purposes for a better understanding of various types of diseases drives the segment growth.

Based on technique, the ELISA segment generated around two-fifths of the global antinuclear antibody test market revenue in 2021, and is expected to lead the trail by 2031. The same segment would also portray the fastest CAGR of 15.67% from 2022-2031. This is because the ELISA test is quick and produces data more quickly than other testing methods.

Based on application, the rheumatoid arthritis segment held more than two-thirds of the global antinuclear antibody test market revenue in 2021. The same segment would also manifest the fastest CAGR of 15.46% from 2022 to 2031. This is attributed to the growing elderly population and increase in cases of rheumatoid arthritis across the world.

By end-use, the hospitals segment contributed to around two-fifths of the global antinuclear antibody test market share in 2021, and is expected to retain its dominance by 2031. Increase in patient satisfaction, outpatient services, and enhanced home care facilities offered by hospitals fuel the growth of the segment. The physician office laboratories segment, on the other hand, is expected to exhibit the fastest CAGR of 15.97% from 2022 to 2031.

Based on region, North America held the major share in 2021, generating nearly two-fifths of the global antinuclear antibody test market. Increasing prevalence of autoimmune illnesses propels the market growth. The Asia-Pacific region, simultaneously, would cite the fastest CAGR of 17.1% throughout the forecast period. With the growing population on board, the likelihood of developing autoimmune diseases has increased significantly. The other provinces studied through the report include Europe and LAMEA.

Purchase the Report: https://www.alliedmarketresearch.com/purchase-enquiry/4259

Our Market Research Solution Provides You Answer to Below Mentioned Question:

• Which are the driving factors responsible for the growth of market?
• Which are the roadblock factors of this market?
• What are the new opportunities, by which market will grow in coming years?
• What are the trends of this market?
• Which are main factors responsible for new product launch?
• How big is the global & regional market in terms of revenue, sales and production?
• How far will the market grow in forecast period in terms of revenue, sales and production?
• Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
• How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
• Which region has more opportunities?

By Region Outlook

• North America
(U.S., Canada, Mexico)
• Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
• Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
• LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

Contact Details:

David Correa
USA/Canada (Toll-Free): +1-800-792-5285, +1-503-894-6022
help@alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains.

This release was published on openPR.